The introduction of amivantamab represents a exciting advance for people battling cancers with c-MET dysregulation. This innovative molecule, a selective inhibitor of multiple MET kinase plus human epidermal growth https://orlandohzzl411017.wikicorrespondence.com/6648044/amivantamab_a_promising_hope_for_c_met_driven_cancers